biotech stocks

AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

New York — November 25, 2025 — Axsome Therapeutics (NASDAQ: AXSM) heads into Tuesday’s session trading just below fresh record highs, powered by blockbuster growth from its depression drug Auvelity, the launch of migraine pill Symbravo, and a rapidly expanding

25 November 2025

NASDAQ:AXSM

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (NASDAQ: ARVN) jumped in double digits on November 18, 2025 amid a focused pipeline reset, FDA momentum for vepdegestrant and attention at the Jefferies London Healthcare Conference. ARVN stock pops on November 18, 2025 Arvinas shares are in rally

18 November 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in

17 November 2025

Biotechnology · Cancer Research · Investment News · NASDAQ:GLMD · Pharmaceuticals · Stock Market

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

What Zymeworks Announced Today Before the U.S. market open on November 17, 2025, Vancouver‑based Zymeworks Inc. (ZYME) released topline Phase 3 data from its pivotal HERIZON‑GEA‑01 study, evaluating Ziihera (zanidatamab‑hrii) in first‑line treatment of HER2‑positive locally advanced or metastatic gastroesophageal

17 November 2025

Biotechnology · Cancer Research · Clinical Trials · Healthcare News · NASDAQ:BGNE · NASDAQ:JAZZ · NASDAQ:ZYME · Stock Market

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab,

3 November 2025

Biotech · Cancer Research · Immunotherapy · Medical Innovation · NASDAQ:IOVA · Stock Analysis

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases gurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than

30 October 2025

Biotech · FDA Approval · Investment · Pharma News · Stock Market

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening

27 October 2025

Biotechnology · CRISPR · Gene Editing · Pharmaceutical Industry · Stock Market

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

Stock Price Rollercoaster in 2025 CRISPR Therapeutics’ stock has been on a wild ride this year. As of midday October 27, CRSP hovered around $67 per share – off its highs but still up dramatically from early 2025 levels genengnews.com.

27 October 2025

Biotechnology · CRISPR · Gene Editing · Investment Analysis · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · Stock Market

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to

24 October 2025

Biotechnology · Cancer Research · Medical News · NASDAQ:INBX · Pharma Industry · Stock Market

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the day finviz.com. This marked BEAM’s highest price since early 2024

20 October 2025

Biotechnology · Financial News · Gene Editing · Investment · NASDAQ:BEAM · Stock Market

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 marketbeat.com, roughly flat

19 October 2025

Biotechnology · Healthcare Industry · Investment Analysis · NASDAQ:VKTX · Obesity Drugs · Stock Market

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at

19 October 2025

Biotechnology · Gene Editing · Healthcare Innovation · Investment Analysis · NASDAQ:CRSP · Stock Market